MedDiet Adherence Doesn't Affect Acute Heart Failure Mortality

Share this content:
MedDiet Adherence Doesn't Affect Acute Heart Failure Mortality
MedDiet Adherence Doesn't Affect Acute Heart Failure Mortality

THURSDAY, Dec. 7, 2017 (HealthDay News) -- For patients with acute heart failure, adherence to the Mediterranean diet (MedDiet) does not influence long-term mortality, according to a study published online Dec. 6 in JACC: Heart Failure.

Òscar Miró, Ph.D., from the University of Barcelona in Spain, and colleagues conducted a prospective study involving patients with acute heart failure in seven Spanish emergency departments. Data were included for 991 patients, of whom 52.9 percent were adherent to the MedDiet.

The researchers observed no significant differences in survival between adherent and nonadherent patients after a mean follow-up of 2.1 ± 1.3 years (hazard ratio of adherents [HRadh], 0.86; 95 percent confidence interval [CI], 0.73 to 1.02). For the whole cohort, the one-year cumulative emergency department revisit was 24.5 percent (HRadh, 1.10; 95 percent CI, 0.84 to 1.42), hospitalization 43.7 percent (HRadh, 0.74; 95 percent CI, 0.61 to 0.90), death 22.7 percent (HRadh, 1.05; 95 percent CI, 0.8 to 1.38), and combined end point 66.8 percent (HRadh, 0.89; 95 percent CI, 0.76 to 1.04). Similar results were seen after adjustment for confounding variables, with no statistically significant differences in mortality (HRadh, 0.94; 95 percent CI, 0.80 to 1.13); lower one-year hospitalization for adherents persisted (HRadh, 0.76; 95 percent CI, 0.62 to 0.93).

"Adherence to the MedDiet did not influence long-term mortality after an episode of acute heart failure, but it was associated with decreased rates of rehospitalization during the next year," the authors write.

The research group received funding from Orion Pharma and Novartis.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »